BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis. 2006;12:744–751. [PMID: 16704830 DOI: 10.3201/eid1205.050681] [Cited by in Crossref: 129] [Cited by in F6Publishing: 119] [Article Influence: 8.6] [Reference Citation Analysis]
Number Citing Articles
1 Menzies D, Benedetti A, Paydar A, Royce S, Madhukar P, Burman W, Vernon A, Lienhardt C. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 2009;6:e1000150. [PMID: 20101802 DOI: 10.1371/journal.pmed.1000150] [Cited by in Crossref: 111] [Cited by in F6Publishing: 103] [Article Influence: 10.1] [Reference Citation Analysis]
2 Cruz AT, Garcia-prats AJ, Furin J, Seddon JA. Treatment of Multidrug-Resistant Tuberculosis Infection in Children. Pediatric Infectious Disease Journal 2018;37:1061-4. [DOI: 10.1097/inf.0000000000002135] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
3 Person AK, Sterling TR. Treatment of latent tuberculosis infection in HIV: shorter or longer? Curr HIV/AIDS Rep 2012;9:259-66. [PMID: 22581360 DOI: 10.1007/s11904-012-0120-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
4 Cowger TL, Thai LH, Duong BD, Danyuttapolchai J, Kittimunkong S, Nhung NV, Nhan DT, Monkongdee P, Thoa CK, Khanh VT, Nateniyom S, Yen NTB, Ngoc DV, Thinh T, Whitehead S, Pevzner ES. Programmatic Evaluation of an Algorithm for Intensified Tuberculosis Case Finding and Isoniazid Preventive Therapy for People Living With HIV in Thailand and Vietnam. J Acquir Immune Defic Syndr 2017;76:512-21. [PMID: 29023251 DOI: 10.1097/QAI.0000000000001551] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
5 Sumner T, Houben RM, Rangaka MX, Maartens G, Boulle A, Wilkinson RJ, White RG. Post-treatment effect of isoniazid preventive therapy on tuberculosis incidence in HIV-infected individuals on antiretroviral therapy. AIDS 2016;30:1279-86. [PMID: 26950316 DOI: 10.1097/QAD.0000000000001078] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
6 Moolphate S, Lawpoolsri S, Pungrassami P, Sanguanwongse N, Yamada N, Kaewkungwal J. Barriers to and motivations for the implementation of a treatment programme for latent tuberculosis infection using isoniazid for people living with HIV, in upper northern Thailand. Glob J Health Sci 2013;5:60-70. [PMID: 23777722 DOI: 10.5539/gjhs.v5n4p60] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
7 Dlamini NC, Ji DD, Chien LY. Factors associated with isoniazid resistant tuberculosis among human immunodeficiency virus positive patients in Swaziland: a case-control study. BMC Infect Dis 2019;19:731. [PMID: 31429717 DOI: 10.1186/s12879-019-4384-6] [Reference Citation Analysis]
8 Moonan PK, Nair SA, Agarwal R, Chadha VK, Dewan PK, Gupta UD, Ho CS, Holtz TH, Kumar AM, Kumar N, Kumar P, Maloney SA, Mase SR, Oeltmann JE, Paramasivan CN, Parmar MM, Rade KK, Ramachandran R, Rao R, Salhorta VS, Sarin R, Sarin S, Sachdeva KS, Selvaraju S, Singla R, Surie D, Tonsing J, Tripathy SP, Khaparde SD. Tuberculosis preventive treatment: the next chapter of tuberculosis elimination in India. BMJ Glob Health 2018;3:e001135. [PMID: 30364389 DOI: 10.1136/bmjgh-2018-001135] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
9 Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, Efron A, Moore RD, Chaisson RE, Durovni B. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2007;21:1441-1448. [PMID: 17589190 DOI: 10.1097/qad.0b013e328216f441] [Cited by in Crossref: 189] [Cited by in F6Publishing: 119] [Article Influence: 13.5] [Reference Citation Analysis]
10 Huaman MA, Sterling TR. Treatment of Latent Tuberculosis Infection-An Update. Clin Chest Med 2019;40:839-48. [PMID: 31731988 DOI: 10.1016/j.ccm.2019.07.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
11 Kasprowicz VO, Churchyard G, Lawn SD, Squire SB, Lalvani A. Diagnosing latent tuberculosis in high-risk individuals: rising to the challenge in high-burden areas. J Infect Dis 2011;204 Suppl 4:S1168-78. [PMID: 21996699 DOI: 10.1093/infdis/jir449] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
12 Pathmanathan I, Ahmedov S, Pevzner E, Anyalechi G, Modi S, Kirking H, Cavanaugh JS. TB preventive therapy for people living with HIV: key considerations for scale-up in resource-limited settings. Int J Tuberc Lung Dis 2018;22:596-605. [PMID: 29862942 DOI: 10.5588/ijtld.17.0758] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 10.5] [Reference Citation Analysis]
13 Dodani SK, Nasim A, Aziz T, Naqvi A. The efficacy of isoniazid prophylaxis in renal transplant recipients in a high tuberculosis burden country. Transpl Infect Dis 2021;:e13709. [PMID: 34331355 DOI: 10.1111/tid.13709] [Reference Citation Analysis]
14 Campbell JR, Trajman A, Cook VJ, Johnston JC, Adjobimey M, Ruslami R, Eisenbeis L, Fregonese F, Valiquette C, Benedetti A, Menzies D. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials. Lancet Infect Dis 2020;20:318-29. [PMID: 31866327 DOI: 10.1016/S1473-3099(19)30575-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
15 Habib AG. Effect of Pre-Medication on Early Adverse Reactions Following Antivenom Use in Snakebite: A Systematic Review and Meta-Analysis. Drug Safety 2011;34:869-80. [DOI: 10.2165/11592050-000000000-00000] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
16 Reddy KP, Brady MF, Gilman RH, Coronel J, Navincopa M, Ticona E, Chavez G, Sánchez E, Rojas C, Solari L, Valencia J, Pinedo Y, Benites C, Friedland JS, Moore DA. Microscopic observation drug susceptibility assay for tuberculosis screening before isoniazid preventive therapy in HIV-infected persons. Clin Infect Dis 2010;50:988-96. [PMID: 20192727 DOI: 10.1086/651081] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
17 Turner RD, Chiu C, Churchyard GJ, Esmail H, Lewinsohn DM, Gandhi NR, Fennelly KP. Tuberculosis Infectiousness and Host Susceptibility. J Infect Dis 2017;216:S636-43. [PMID: 29112746 DOI: 10.1093/infdis/jix361] [Cited by in Crossref: 41] [Cited by in F6Publishing: 25] [Article Influence: 10.3] [Reference Citation Analysis]
18 Getahun H, Granich R, Sculier D, Gunneberg C, Blanc L, Nunn P, Raviglione M. Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS. 2010;24 Suppl 5:S57-S65. [PMID: 21079430 DOI: 10.1097/01.aids.0000391023.03037.1f] [Cited by in Crossref: 52] [Cited by in F6Publishing: 63] [Article Influence: 5.2] [Reference Citation Analysis]
19 Charles MK, Lindegren ML, Wester CW, Blevins M, Sterling TR, Dung NT, Dusingize JC, Avit-Edi D, Durier N, Castelnuovo B, Nakigozi G, Cortes CP, Ballif M, Fenner L; International epidemiology Databases to Evaluate AIDS (IeDEA) Collaboration. Implementation of Tuberculosis Intensive Case Finding, Isoniazid Preventive Therapy, and Infection Control ("Three I's") and HIV-Tuberculosis Service Integration in Lower Income Countries. PLoS One 2016;11:e0153243. [PMID: 27073928 DOI: 10.1371/journal.pone.0153243] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
20 Wejse C. Tuberculosis elimination in the post Millennium Development Goals era. Int J Infect Dis 2015;32:152-5. [PMID: 25809772 DOI: 10.1016/j.ijid.2014.11.020] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
21 Lee SS, Meintjes G, Kamarulzaman A, Leung CC. Management of tuberculosis and latent tuberculosis infection in human immunodeficiency virus-infected persons. Respirology 2013;18:912-22. [PMID: 23682586 DOI: 10.1111/resp.12120] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
22 Wang PH, Lin CH, Chang TH, Wu CS. Chest roentgenography is complementary to interferon-gamma release assay in latent tuberculosis infection screening of rheumatic patients. BMC Pulm Med 2020;20:232. [PMID: 32867745 DOI: 10.1186/s12890-020-01274-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Esmail H, Barry CE 3rd, Wilkinson RJ. Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies. Drug Discov Today 2012;17:514-21. [PMID: 22198298 DOI: 10.1016/j.drudis.2011.12.013] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 6.3] [Reference Citation Analysis]
24 Kendall EA, Azman AS, Maartens G, Boulle A, Wilkinson RJ, Dowdy DW, Rangaka MX. Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting. AIDS 2019;33:525-36. [PMID: 30325773 DOI: 10.1097/QAD.0000000000002053] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
25 Francisco-Cruz A, Mata-Espinosa D, Estrada-Parra S, Xing Z, Hernández-Pando R. Immunotherapeutic effects of recombinant adenovirus encoding granulocyte-macrophage colony-stimulating factor in experimental pulmonary tuberculosis. Clin Exp Immunol. 2013;171:283-297. [PMID: 23379435 DOI: 10.1111/cei.12015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
26 Basu Roy R, Whittaker E, Seddon JA, Kampmann B. Tuberculosis susceptibility and protection in children. Lancet Infect Dis 2019;19:e96-e108. [PMID: 30322790 DOI: 10.1016/S1473-3099(18)30157-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 15] [Article Influence: 10.7] [Reference Citation Analysis]
27 Houben RM, Sumner T, Grant AD, White RG. Ability of preventive therapy to cure latent Mycobacterium tuberculosis infection in HIV-infected individuals in high-burden settings. Proc Natl Acad Sci U S A 2014;111:5325-30. [PMID: 24706842 DOI: 10.1073/pnas.1317660111] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 4.7] [Reference Citation Analysis]
28 Kall MM, Coyne KM, Garrett NJ, Boyd AE, Ashcroft AT, Reeves I, Anderson J, Bothamley GH. Latent and subclinical tuberculosis in HIV infected patients: a cross-sectional study. BMC Infect Dis 2012;12:107. [PMID: 22558946 DOI: 10.1186/1471-2334-12-107] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
29 Shah NS, Moodley P, Babaria P, Moodley S, Ramtahal M, Richardson J, Heysell S, Li X, Moll A, Friedland G, Sturm AW, Gandhi NR. Rapid Diagnosis of Tuberculosis and Multidrug Resistance by the Microscopic-Observation Drug-Susceptibility Assay. Am J Respir Crit Care Med 2011;183:1427-33. [DOI: 10.1164/rccm.201009-1449oc] [Cited by in Crossref: 29] [Cited by in F6Publishing: 8] [Article Influence: 2.9] [Reference Citation Analysis]
30 Rangaka MX, Cavalcante SC, Marais BJ, Thim S, Martinson NA, Swaminathan S, Chaisson RE. Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection. Lancet 2015;386:2344-53. [PMID: 26515679 DOI: 10.1016/S0140-6736(15)00323-2] [Cited by in Crossref: 99] [Cited by in F6Publishing: 46] [Article Influence: 16.5] [Reference Citation Analysis]
31 Graham SM. The management of infection with Mycobacterium tuberculosis in young children post-2015: an opportunity to close the policy-practice gap. Expert Review of Respiratory Medicine 2017;11:41-9. [DOI: 10.1080/17476348.2016.1267572] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
32 Maheswaran H, Barton P. Intensive case finding and isoniazid preventative therapy in HIV infected individuals in Africa: economic model and value of information analysis. PLoS One 2012;7:e30457. [PMID: 22291958 DOI: 10.1371/journal.pone.0030457] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
33 Kunkel A, Crawford FW, Shepherd J, Cohen T. Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic. AIDS 2016;30:2715-23. [PMID: 27782966 DOI: 10.1097/QAD.0000000000001235] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
34 Li TL, Chan TH, Wang CH, Jou R, Yu MC, Putri DU, Lee CH, Lin YH. Acquired Resistance to Isoniazid During Isoniazid Monotherapy in a Subject with Latent Infection Following Household Rifampicin-Resistant Tuberculosis Contact: A Case Report. Infect Drug Resist 2021;14:1505-9. [PMID: 33907428 DOI: 10.2147/IDR.S304799] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Barth RE, Mudrikova T, Hoepelman AI. Interferon-gamma release assays (IGRAs) in high-endemic settings: could they play a role in optimizing global TB diagnostics? International Journal of Infectious Diseases 2008;12:e1-6. [DOI: 10.1016/j.ijid.2008.03.026] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
36 Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, McIntyre JA, Gray GE, Chaisson RE. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011;365:11-20. [PMID: 21732833 DOI: 10.1056/NEJMoa1005136] [Cited by in Crossref: 202] [Cited by in F6Publishing: 97] [Article Influence: 20.2] [Reference Citation Analysis]
37 Pierce CW. Subclinical Tuberculosis: Some Flies in the Ointment. Am J Respir Crit Care Med 2021;203:1327-8. [PMID: 33689597 DOI: 10.1164/rccm.202101-0227LE] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Sumner T, Scriba TJ, Penn-Nicholson A, Hatherill M, White RG. Potential population level impact on tuberculosis incidence of using an mRNA expression signature correlate-of-risk test to target tuberculosis preventive therapy. Sci Rep 2019;9:11126. [PMID: 31366947 DOI: 10.1038/s41598-019-47645-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
39 Havumaki J, Cohen T, Zhai C, Miller JC, Guikema SD, Eisenberg MC, Zelner J. Protective impacts of household-based tuberculosis contact tracing are robust across endemic incidence levels and community contact patterns. PLoS Comput Biol 2021;17:e1008713. [PMID: 33556077 DOI: 10.1371/journal.pcbi.1008713] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Lee SH, Yim JJ, Kim HJ, Shim TS, Seo HS, Cho YS, Lee HK, Lee YM, Lee EJ, Lew WJ. Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak. Epidemiol Infect 2012;140:1028-35. [PMID: 21835069 DOI: 10.1017/S0950268811001476] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
41 Gupta A, Singh SK, Anupurba S. Mutations at embB306 codon and their association with multidrug resistant M. tuberculosis clinical isolates. Indian J Med Microbiol 2015;33:387-92. [PMID: 26068341 DOI: 10.4103/0255-0857.158560] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
42 den Boon S, Matteelli A, Getahun H. Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2016;20:1065-71. [PMID: 27393541 DOI: 10.5588/ijtld.15.0908] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
43 Rutherford ME, Hill PC, Triasih R, Sinfield R, van Crevel R, Graham SM. Preventive therapy in children exposed to Mycobacterium tuberculosis: problems and solutions. Trop Med Int Health 2012;17:1264-73. [PMID: 22862994 DOI: 10.1111/j.1365-3156.2012.03053.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
44 Pienaar E, Linderman JJ, Kirschner DE. Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomas. PLoS One 2018;13:e0196322. [PMID: 29746491 DOI: 10.1371/journal.pone.0196322] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
45 Masini EO, Sitienei J, Weyeinga H. Outcomes of isoniazid prophylaxis among HIV-infected children attending routine HIV care in Kenya. Public Health Action 2013;3:204-8. [PMID: 26393030 DOI: 10.5588/pha.13.0013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
46 Teklay G, Teklu T, Legesse B, Tedla K, Klinkenberg E. Barriers in the implementation of isoniazid preventive therapy for people living with HIV in Northern Ethiopia: a mixed quantitative and qualitative study. BMC Public Health 2016;16:840. [PMID: 27543096 DOI: 10.1186/s12889-016-3525-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
47 Kerkhoff AD, Kranzer K, Samandari T, Nakiyingi-Miiro J, Whalen CC, Harries AD, Lawn SD. Systematic review of TST responses in people living with HIV in under-resourced settings: implications for isoniazid preventive therapy. PLoS One 2012;7:e49928. [PMID: 23209621 DOI: 10.1371/journal.pone.0049928] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
48 Lipsitch M, Cohen T, Murray M, Levin BR. Antiviral resistance and the control of pandemic influenza. PLoS Med 2007;4:e15. [PMID: 17253900 DOI: 10.1371/journal.pmed.0040015] [Cited by in Crossref: 149] [Cited by in F6Publishing: 128] [Article Influence: 10.6] [Reference Citation Analysis]
49 Marais BJ, Ayles H, Graham SM, Godfrey-faussett P. Screening and Preventive Therapy for Tuberculosis. Clinics in Chest Medicine 2009;30:827-46. [DOI: 10.1016/j.ccm.2009.08.012] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
50 Rhines AS, Feldman MW, Bendavid E. Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting. AIDS 2018;32:2129-40. [PMID: 30096067 DOI: 10.1097/QAD.0000000000001959] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, Den Boon S, Borroto Gutierrez SM, Bruchfeld J, Burhan E, Cavalcante S, Cedillos R, Chaisson R, Chee CB, Chesire L, Corbett E, Dara M, Denholm J, de Vries G, Falzon D, Ford N, Gale-Rowe M, Gilpin C, Girardi E, Go UY, Govindasamy D, D Grant A, Grzemska M, Harris R, Horsburgh CR Jr, Ismayilov A, Jaramillo E, Kik S, Kranzer K, Lienhardt C, LoBue P, Lönnroth K, Marks G, Menzies D, Migliori GB, Mosca D, Mukadi YD, Mwinga A, Nelson L, Nishikiori N, Oordt-Speets A, Rangaka MX, Reis A, Rotz L, Sandgren A, Sañé Schepisi M, Schünemann HJ, Sharma SK, Sotgiu G, Stagg HR, Sterling TR, Tayeb T, Uplekar M, van der Werf MJ, Vandevelde W, van Kessel F, van't Hoog A, Varma JK, Vezhnina N, Voniatis C, Vonk Noordegraaf-Schouten M, Weil D, Weyer K, Wilkinson RJ, Yoshiyama T, Zellweger JP, Raviglione M. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 2015;46:1563-76. [PMID: 26405286 DOI: 10.1183/13993003.01245-2015] [Cited by in F6Publishing: 260] [Reference Citation Analysis]
52 Hirama T, Hagiwara K, Kanazawa M. Tuberculosis screening programme using the QuantiFERON-TB Gold test and chest computed tomography for healthcare workers accidentally exposed to patients with tuberculosis. J Hosp Infect 2011;77:257-62. [PMID: 21316804 DOI: 10.1016/j.jhin.2010.11.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
53 Swaminathan S, Menon PA, Gopalan N, Perumal V, Santhanakrishnan RK, Ramachandran R, Chinnaiyan P, Iliayas S, Chandrasekaran P, Navaneethapandian PD. Efficacy of a six-month versus a 36-month regimen for prevention of tuberculosis in HIV-infected persons in India: a randomized clinical trial. PLoS One. 2012;7:e47400. [PMID: 23251327 DOI: 10.1371/journal.pone.0047400] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
54 Bruins WS, van Leth F. Effect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic review. Infect Dis (Lond) 2017;49:161-9. [PMID: 27911140 DOI: 10.1080/23744235.2016.1262059] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
55 Corbett EL, MacPherson P. Tuberculosis screening in high human immunodeficiency virus prevalence settings: turning promise into reality. Int J Tuberc Lung Dis 2013;17:1125-38. [PMID: 23928165 DOI: 10.5588/ijtld.13.0117] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
56 Drain PK, Bajema KL, Dowdy D, Dheda K, Naidoo K, Schumacher SG, Ma S, Meermeier E, Lewinsohn DM, Sherman DR. Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection. Clin Microbiol Rev 2018;31:e00021-18. [PMID: 30021818 DOI: 10.1128/CMR.00021-18] [Cited by in Crossref: 132] [Cited by in F6Publishing: 66] [Article Influence: 44.0] [Reference Citation Analysis]
57 Szkwarko D, Hirsch-Moverman Y, Du Plessis L, Du Preez K, Carr C, Mandalakas AM. Child contact management in high tuberculosis burden countries: A mixed-methods systematic review. PLoS One 2017;12:e0182185. [PMID: 28763500 DOI: 10.1371/journal.pone.0182185] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 11.0] [Reference Citation Analysis]
58 Churchyard GJ, Scano F, Grant AD, Chaisson RE. Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. J Infect Dis 2007;196 Suppl 1:S52-62. [PMID: 17624827 DOI: 10.1086/518662] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 3.3] [Reference Citation Analysis]
59 Abad CLR, Deziel PJ, Razonable RR. Treatment of latent TB Infection and the risk of tuberculosis after solid organ transplantation: Comprehensive review. Transpl Infect Dis 2019;21:e13178. [PMID: 31541575 DOI: 10.1111/tid.13178] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
60 Gopalan N, Chandrasekaran P, Swaminathan S, Tripathy S. Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis. AIDS Res Ther 2016;13:34. [PMID: 27708678 DOI: 10.1186/s12981-016-0118-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
61 Lee SW, Jang YS, Park CM, Kang HY, Koh W, Yim J, Jeon K. The Role of Chest CT Scanning in TB Outbreak Investigation. Chest 2010;137:1057-64. [DOI: 10.1378/chest.09-1513] [Cited by in Crossref: 48] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
62 Nagu TJ, Aboud S, Matee MI, Maeurer MJ, Fawzi WW, Mugusi F. Effects of isoniazid resistance on TB treatment outcomes under programmatic conditions in a high-TB and -HIV setting: a prospective multicentre study. J Antimicrob Chemother 2017;72:876-81. [PMID: 27999054 DOI: 10.1093/jac/dkw503] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
63 Ahmad Khan F, Verkuijl S, Parrish A, Chikwava F, Ntumy R, El-Sadr W, Howard AA. Performance of symptom-based tuberculosis screening among people living with HIV: not as great as hoped. AIDS 2014;28:1463-72. [PMID: 24681417 DOI: 10.1097/QAD.0000000000000278] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
64 Meyssonnier V, Veziris N, Bastian S, Texier-maugein J, Jarlier V, Robert J. Increase in primary drug resistance of Mycobacterium tuberculosis in younger birth cohorts in France. Journal of Infection 2012;64:589-95. [DOI: 10.1016/j.jinf.2012.01.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
65 Stagg HR, Lipman MC, McHugh TD, Jenkins HE. Isoniazid-resistant tuberculosis: a cause for concern? Int J Tuberc Lung Dis 2017;21:129-39. [PMID: 28234075 DOI: 10.5588/ijtld.16.0716] [Cited by in Crossref: 40] [Cited by in F6Publishing: 26] [Article Influence: 13.3] [Reference Citation Analysis]
66 Cox H, Nicol MP. Tuberculosis eradication: renewed commitment and global investment required. Lancet Infect Dis 2018;18:228-9. [PMID: 29223584 DOI: 10.1016/S1473-3099(17)30692-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
67 Sherman DR, Gagneux S. Estimating the mutation rate of Mycobacterium tuberculosis during infection. Nat Genet 2011;43:400-1. [PMID: 21522177 DOI: 10.1038/ng.815] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
68 Sharma SK, Mohanan S, Sharma A. Relevance of latent TB infection in areas of high TB prevalence. Chest. 2012;142:761-773. [PMID: 22948580 DOI: 10.1378/chest.12-0142] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
69 Seddon JA, Garcia-Prats AJ, Purchase SE, Osman M, Demers AM, Hoddinott G, Crook AM, Owen-Powell E, Thomason MJ, Turkova A, Gibb DM, Fairlie L, Martinson N, Schaaf HS, Hesseling AC. Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP). Trials 2018;19:693. [PMID: 30572905 DOI: 10.1186/s13063-018-3070-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
70 Menzies HJ, Moalosi G, Anisimova V, Gammino V, Sentle C, Bachhuber MA, Bile E, Radisowa K, Kachuwaire O, Basotli J, Maribe T, Makombe R, Shepherd J, Kim B, Samandari T, El-Halabi S, Chirenda J, Cain KP. Increase in anti-tuberculosis drug resistance in Botswana: results from the fourth National Drug Resistance Survey. Int J Tuberc Lung Dis 2014;18:1026-33. [PMID: 25189548 DOI: 10.5588/ijtld.13.0749] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
71 Collin SM, Wurie F, Muzyamba MC, de Vries G, Lönnroth K, Migliori GB, Abubakar I, Anderson SR, Zenner D. Effectiveness of interventions for reducing TB incidence in countries with low TB incidence: a systematic review of reviews. Eur Respir Rev 2019;28:180107. [PMID: 31142548 DOI: 10.1183/16000617.0107-2018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
72 Bracchi M, van Halsema C, Post F, Awosusi F, Barbour A, Bradley S, Coyne K, Dixon-Williams E, Freedman A, Jelliman P, Khoo S, Leen C, Lipman M, Lucas S, Miller R, Seden K, Pozniak A. British HIV Association guidelines for the management of tuberculosis in adults living with HIV 2019. HIV Med 2019;20 Suppl 6:s2-s83. [PMID: 31152481 DOI: 10.1111/hiv.12748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
73 Wyndham-Thomas C, Schepers K, Dirix V, Mascart F, Van Vooren JP, Goffard JC. Implementation of latent tuberculosis screening in HIV care centres: evaluation in a low tuberculosis incidence setting. Epidemiol Infect 2016;144:703-11. [PMID: 26211466 DOI: 10.1017/S0950268815001594] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
74 Lawn SD, Wood R, Wilkinson RJ. Changing concepts of "latent tuberculosis infection" in patients living with HIV infection. Clin Dev Immunol 2011;2011:980594. [PMID: 20936108 DOI: 10.1155/2011/980594] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 3.5] [Reference Citation Analysis]
75 Howard AA, Gasana M, Getahun H, Harries A, Lawn SD, Miller B, Nelson L, Sitienei J, Coggin WL. PEPFAR support for the scaling up of collaborative TB/HIV activities. J Acquir Immune Defic Syndr 2012;60 Suppl 3:S136-44. [PMID: 22797735 DOI: 10.1097/QAI.0b013e31825cfe8e] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
76 Pozniak AL, Coyne KM, Miller RF, Lipman MC, Freedman AR, Ormerod LP, Johnson MA, Collins S, Lucas SB; BHIVA Guidelines Subcommittee. British HIV Association guidelines for the treatment of TB/HIV coinfection 2011. HIV Med 2011;12:517-24. [PMID: 21951595 DOI: 10.1111/j.1468-1293.2011.00954.x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 64] [Article Influence: 8.3] [Reference Citation Analysis]
77 Kasibante J, Rutakingirwa MK, Kagimu E, Ssebambulidde K, Ellis J, Tugume L, Mpoza E, Cresswell F, Meya DB. Tuberculosis preventive therapy (TPT) to prevent tuberculosis co-infection among adults with HIV-associated cryptococcal meningitis: A clinician's perspective. J Clin Tuberc Other Mycobact Dis 2020;20:100180. [PMID: 32875123 DOI: 10.1016/j.jctube.2020.100180] [Reference Citation Analysis]
78 Denkinger CM, Pai M, Dowdy DW. Do we need to detect isoniazid resistance in addition to rifampicin resistance in diagnostic tests for tuberculosis? PLoS One 2014;9:e84197. [PMID: 24404155 DOI: 10.1371/journal.pone.0084197] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
79 Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;CD000171. [PMID: 20091503 DOI: 10.1002/14651858.cd000171.pub3] [Cited by in Crossref: 119] [Cited by in F6Publishing: 180] [Article Influence: 10.8] [Reference Citation Analysis]
80 Grace SG. Barriers to the implementation of isoniazid preventive therapy for tuberculosis in children in endemic settings: A review. J Paediatr Child Health 2019;55:278-84. [PMID: 30604557 DOI: 10.1111/jpc.14359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
81 Fox GJ, Oxlade O, Menzies D. Fluoroquinolone Therapy for the Prevention of Multidrug-Resistant Tuberculosis in Contacts. A Cost-Effectiveness Analysis. Am J Respir Crit Care Med 2015;192:229-37. [DOI: 10.1164/rccm.201501-0069oc] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
82 Getahun H, Matteelli A, Abubakar I, Hauer B, Pontali E, Migliori GB. Advancing global programmatic management of latent tuberculosis infection for at risk populations. Eur Respir J 2016;47:1327-30. [DOI: 10.1183/13993003.00449-2016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
83 Atey TM, Bitew H, Asgedom SW, Endrias A, Berhe DF. Does Isoniazid Preventive Therapy Provide Better Treatment Outcomes in HIV-Infected Individuals in Northern Ethiopia? A Retrospective Cohort Study. AIDS Res Treat 2020;2020:7025738. [PMID: 32411454 DOI: 10.1155/2020/7025738] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
84 Nicolau I, Ling D, Tian L, Lienhardt C, Pai M. Research questions and priorities for tuberculosis: a survey of published systematic reviews and meta-analyses. PLoS One 2012;7:e42479. [PMID: 22848764 DOI: 10.1371/journal.pone.0042479] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
85 Edessa D, Likisa J. A Description of Mortality Associated with IPT plus ART Compared to ART Alone among HIV-Infected Individuals in Addis Ababa, Ethiopia: A Cohort Study. PLoS One 2015;10:e0137492. [PMID: 26348618 DOI: 10.1371/journal.pone.0137492] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
86 Patel DB, Patel KD, Prajapati NP, Patel KR, Rajani DP, Rajani SD, Shah NS, Zala DD, Patel HD. Design, Synthesis, and Biological and In Silico Study of Fluorine‐Containing Quinoline Hybrid Thiosemicarbazide Analogues. J Heterocyclic Chem 2019;56:2235-52. [DOI: 10.1002/jhet.3617] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
87 Mills HL, Cohen T, Colijn C. Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis. Sci Transl Med 2013;5:180ra49. [PMID: 23576815 DOI: 10.1126/scitranslmed.3005260] [Cited by in Crossref: 17] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
88 Lawn SD, Wood R, De Cock KM, Kranzer K, Lewis JJ, Churchyard GJ. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. The Lancet Infectious Diseases 2010;10:489-98. [DOI: 10.1016/s1473-3099(10)70078-5] [Cited by in Crossref: 125] [Cited by in F6Publishing: 80] [Article Influence: 11.4] [Reference Citation Analysis]
89 Cruz JN, Costa JFS, Khayat AS, Kuca K, Barros CAL, Neto AMJC. Molecular dynamics simulation and binding free energy studies of novel leads belonging to the benzofuran class inhibitors of Mycobacterium tuberculosis Polyketide Synthase 13. J Biomol Struct Dyn 2019;37:1616-27. [PMID: 29633908 DOI: 10.1080/07391102.2018.1462734] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 7.7] [Reference Citation Analysis]
90 Wangari IM, Trauer J, Stone L. Modelling heterogeneity in host susceptibility to tuberculosis and its effect on public health interventions. PLoS One 2018;13:e0206603. [PMID: 30427891 DOI: 10.1371/journal.pone.0206603] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
91 Churchyard GJ, Swindells S. Controlling latent TB tuberculosis infection in high-burden countries: A neglected strategy to end TB. PLoS Med 2019;16:e1002787. [PMID: 31013273 DOI: 10.1371/journal.pmed.1002787] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 9.5] [Reference Citation Analysis]
92 Blanquer R, Rodrigo T, Casals M, Ruiz Manzano J, García-García JM, Calpe JL, Valencia E, Pascual T, Mir I, Jiménez MÁ, Cañas F, Vidal R, Penas A, Caylà JA; Working Group of the Integrated Programme for Research in Tuberculosis in Spain. Resistance to first-line antituberculosis drugs in Spain, 2010-2011. RETUBES Study. Arch Bronconeumol 2015;51:24-30. [PMID: 25027066 DOI: 10.1016/j.arbres.2014.06.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.9] [Reference Citation Analysis]
93 Maartens G, Wilkinson RJ. Tuberculosis. The Lancet 2007;370:2030-43. [DOI: 10.1016/s0140-6736(07)61262-8] [Cited by in Crossref: 213] [Cited by in F6Publishing: 93] [Article Influence: 15.2] [Reference Citation Analysis]
94 Cohen T, Dye C, Colijn C, Williams B, Murray M. Mathematical models of the epidemiology and control of drug-resistant TB. Expert Rev Respir Med 2009;3:67-79. [PMID: 20477283 DOI: 10.1586/17476348.3.1.67] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
95 Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev 2013;:CD007545. [PMID: 23828580 DOI: 10.1002/14651858.CD007545.pub2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
96 Seddon JA, Godfrey-Faussett P, Hesseling AC, Gie RP, Beyers N, Schaaf HS. Management of children exposed to multidrug-resistant Mycobacterium tuberculosis. Lancet Infect Dis 2012;12:469-79. [PMID: 22373591 DOI: 10.1016/S1473-3099(11)70366-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
97 Vilaplana C, Cardona PJ. The lack of a big picture in tuberculosis: the clinical point of view, the problems of experimental modeling and immunomodulation. The factors we should consider when designing novel treatment strategies. Front Microbiol 2014;5:55. [PMID: 24592258 DOI: 10.3389/fmicb.2014.00055] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
98 Lester R, Hamilton R, Charalambous S, Dwadwa T, Chandler C, Churchyard GJ, Grant AD. Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study. AIDS 2010;24 Suppl 5:S45-8. [PMID: 21079427 DOI: 10.1097/01.aids.0000391021.18284.12] [Cited by in Crossref: 43] [Cited by in F6Publishing: 50] [Article Influence: 4.3] [Reference Citation Analysis]
99 Marais BJ, Schaaf HS, Donald PR. Pediatric TB: issues related to current and future treatment options. Future Microbiology 2009;4:661-75. [DOI: 10.2217/fmb.09.39] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
100 Hamada Y, Getahun H, Tadesse BT, Ford N. HIV-associated tuberculosis. Int J STD AIDS 2021;32:780-90. [PMID: 33612015 DOI: 10.1177/0956462421992257] [Reference Citation Analysis]
101 Lien LT, Hang NT, Kobayashi N, Yanai H, Toyota E, Sakurada S, Thuong PH, Cuong VC, Nanri A, Mizoue T, Matsushita I, Harada N, Higuchi K, Tuan LA, Keicho N. Prevalence and risk factors for tuberculosis infection among hospital workers in Hanoi, Viet Nam. PLoS One 2009;4:e6798. [PMID: 19710920 DOI: 10.1371/journal.pone.0006798] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
102 Akolo C, Bada F, Okpokoro E, Nwanne O, Iziduh S, Usoroh E, Ali T, Ibeziako V, Oladimeji O, Odo M. Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons. World J Virol 2015;4:105-12. [PMID: 25964875 DOI: 10.5501/wjv.v4.i2.105] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
103 Hearn M, Cynamon M, Chen M, Coppins R, Davis J, Joo-On Kang H, Noble A, Tu-Sekine B, Terrot MS, Trombino D. Preparation and antitubercular activities in vitro and in vivo of novel Schiff bases of isoniazid. Eur J Med Chem. 2009;44:4169-4178. [PMID: 19524330 DOI: 10.1016/j.ejmech.2009.05.009] [Cited by in Crossref: 94] [Cited by in F6Publishing: 48] [Article Influence: 7.8] [Reference Citation Analysis]
104 Golub JE, Pronyk P, Mohapi L, Thsabangu N, Moshabela M, Struthers H, Gray GE, McIntyre JA, Chaisson RE, Martinson NA. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009;23:631-636. [PMID: 19525621 DOI: 10.1097/qad.0b013e328327964f] [Cited by in Crossref: 152] [Cited by in F6Publishing: 90] [Article Influence: 13.8] [Reference Citation Analysis]
105 Ford CB, Lin PL, Chase MR, Shah RR, Iartchouk O, Galagan J, Mohaideen N, Ioerger TR, Sacchettini JC, Lipsitch M, Flynn JL, Fortune SM. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet 2011;43:482-6. [PMID: 21516081 DOI: 10.1038/ng.811] [Cited by in Crossref: 304] [Cited by in F6Publishing: 255] [Article Influence: 30.4] [Reference Citation Analysis]
106 Fraisse P. Traitement des infections tuberculeuses latentes. Revue des Maladies Respiratoires 2012;29:579-600. [DOI: 10.1016/j.rmr.2011.07.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
107 Gersh JK, Barnabas RV, Matemo D, Kinuthia J, Feldman Z, Lacourse SM, Mecha J, Warr AJ, Kamene M, Horne DJ. Pulmonary tuberculosis screening in anti-retroviral treated adults living with HIV in Kenya. BMC Infect Dis 2021;21:218. [PMID: 33632173 DOI: 10.1186/s12879-021-05916-z] [Reference Citation Analysis]
108 Salazar-Austin N, Dowdy DW, Chaisson RE, Golub JE. Seventy Years of Tuberculosis Prevention: Efficacy, Effectiveness, Toxicity, Durability, and Duration. Am J Epidemiol 2019;188:2078-85. [PMID: 31364692 DOI: 10.1093/aje/kwz172] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
109 Rangaka MX, Gideon HP, Wilkinson KA, Pai M, Mwansa-Kambafwile J, Maartens G, Glynn JR, Boulle A, Fielding K, Goliath R, Titus R, Mathee S, Wilkinson RJ. Interferon release does not add discriminatory value to smear-negative HIV-tuberculosis algorithms. Eur Respir J 2012;39:163-71. [PMID: 21719487 DOI: 10.1183/09031936.00058911] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
110 Chandra DK, Moll AP, Altice FL, Didomizio E, Andrews L, Shenoi SV. Structural barriers to implementing recommended tuberculosis preventive treatment in primary care clinics in rural South Africa. Glob Public Health 2021;:1-14. [PMID: 33650939 DOI: 10.1080/17441692.2021.1892793] [Reference Citation Analysis]
111 Reid MJA, Arinaminpathy N, Bloom A, Bloom BR, Boehme C, Chaisson R, Chin DP, Churchyard G, Cox H, Ditiu L, Dybul M, Farrar J, Fauci AS, Fekadu E, Fujiwara PI, Hallett TB, Hanson CL, Harrington M, Herbert N, Hopewell PC, Ikeda C, Jamison DT, Khan AJ, Koek I, Krishnan N, Motsoaledi A, Pai M, Raviglione MC, Sharman A, Small PM, Swaminathan S, Temesgen Z, Vassall A, Venkatesan N, van Weezenbeek K, Yamey G, Agins BD, Alexandru S, Andrews JR, Beyeler N, Bivol S, Brigden G, Cattamanchi A, Cazabon D, Crudu V, Daftary A, Dewan P, Doepel LK, Eisinger RW, Fan V, Fewer S, Furin J, Goldhaber-Fiebert JD, Gomez GB, Graham SM, Gupta D, Kamene M, Khaparde S, Mailu EW, Masini EO, McHugh L, Mitchell E, Moon S, Osberg M, Pande T, Prince L, Rade K, Rao R, Remme M, Seddon JA, Selwyn C, Shete P, Sachdeva KS, Stallworthy G, Vesga JF, Vilc V, Goosby EP. Building a tuberculosis-free world: The Lancet Commission on tuberculosis. Lancet 2019;393:1331-84. [PMID: 30904263 DOI: 10.1016/S0140-6736(19)30024-8] [Cited by in Crossref: 139] [Cited by in F6Publishing: 64] [Article Influence: 69.5] [Reference Citation Analysis]
112 Villegas L, Otero L, Sterling TR, Huaman MA, Van der Stuyft P, Gotuzzo E, Seas C. Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin-Mono-Resistant Pulmonary Tuberculosis in Lima, Peru. PLoS One 2016;11:e0152933. [PMID: 27045684 DOI: 10.1371/journal.pone.0152933] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 6.6] [Reference Citation Analysis]
113 Manabe YC, Breen R, Perti T, Girardi E, Sterling TR. Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. J Infect Dis 2009;199:437-44. [PMID: 19090776 DOI: 10.1086/595985] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 4.7] [Reference Citation Analysis]
114 Cattamanchi A, Dantes RB, Metcalfe JZ, Jarlsberg LG, Grinsdale J, Kawamura LM, Osmond D, Hopewell PC, Nahid P. Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clin Infect Dis 2009;48:179-85. [PMID: 19086909 DOI: 10.1086/595689] [Cited by in Crossref: 62] [Cited by in F6Publishing: 67] [Article Influence: 5.2] [Reference Citation Analysis]
115 Yirdaw KD, Teklu AM, Mamuye AT, Zewdu S. Breakthrough tuberculosis disease among people with HIV - Should we be worried? A retrospective longitudinal study. PLoS One 2019;14:e0211688. [PMID: 30716126 DOI: 10.1371/journal.pone.0211688] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
116 Auld AF, Mbofana F, Shiraishi RW, Alfredo C, Sanchez M, Ellerbrock TV, Nelson LJ. Incidence and determinants of tuberculosis among adults initiating antiretroviral therapy--Mozambique, 2004-2008. PLoS One 2013;8:e54665. [PMID: 23349948 DOI: 10.1371/journal.pone.0054665] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
117 Ramos RM, Perez JM, Baptista LA, de Amorim HLN. Interaction of wild type, G68R and L125M isoforms of the arylamine-N-acetyltransferase from Mycobacterium tuberculosis with isoniazid: a computational study on a new possible mechanism of resistance. J Mol Model 2012;18:4013-24. [DOI: 10.1007/s00894-012-1383-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
118 Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Evid Based Child Health. 2014;9:169-294. [PMID: 25404581 DOI: 10.1002/ebch.1962] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
119 van Halsema CL, Fielding KL, Chihota VN, Russell EC, Lewis JJ, Churchyard GJ, Grant AD. Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. AIDS. 2010;24:1051-1055. [PMID: 20299958 DOI: 10.1097/qad.0b013e32833849df] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]